Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Vivo Responses of DC Vaccines Presenting HLA Class I and II Restricted Tumor Epitopes Either by Peptide-pulsing or mRNA Transfection in Melanoma Patients

NCT00243529 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT00243529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00243529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Vivo Responses of DC Vaccines Presenting HLA Class I and II Restricted Tumor Epitopes Either by Peptide-pulsing or mRNA Transfection in Melanoma Patients
Lead sponsor
Radboud University Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2004
Completion date
Not reported
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii or iv